Clinical Trials Logo

MEK Alteration clinical trials

View clinical trials related to MEK Alteration.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04488003 Terminated - Clinical trials for Advanced Solid Tumor

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Start date: January 7, 2021
Phase: Phase 2
Study type: Interventional

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.